HCV E2
Reactivity: Hepatitis C Virus (HCV)
WB, EIA, IFA
Host: Mouse
Monoclonal
unconjugated
Application Notes
Conjugation-ELISA. Western Blot. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Format
Liquid
Concentration
4-5 mg/mL (OD280nm, E0.1% = 1.4)
Buffer
0.01 M PBS, pH 7.2 containing 0.09 % Sodium Azide as preservative and no stabilizing proteins.
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Target
HCV E2
(Hepatitis C Virus Envelope Protein E2 (HCV E2))
Alternative Name
HCV Envelope Glycoprotein E2
Target Type
Viral Protein
Background
Hepatitis C E2 is a virus envelope glycoprotein which forms a heterodimer with the E1 protein. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs are professional antigen presenting cells, critical for host immunity by inducing specific immune responses against a broad variety of pathogens. They act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection.Synonyms: Hepatitis C Virus NS1, gp68, gp70